T细胞受体及其使用方法
By designing nucleic acid molecules that specifically bind to MAGE-A2 and inhibit endogenous TCRs, the challenge of tumor antigen specificity in T-cell therapy has been solved, achieving broad applicability and safe treatment effects for a variety of cancers.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- UNIV HEALTH NETWORK
- Filing Date
- 2020-07-29
- Publication Date
- 2026-07-17
AI Technical Summary
Existing T-cell therapies target tumor antigens that are mostly patient-specific, making it difficult to achieve widespread application. Furthermore, the high polymorphism of HLA genes hinders the specificity of anti-tumor T-cell responses to non-mutated antigens.
A nucleic acid molecule was designed to encode a recombinant T-cell receptor (TCR) that specifically binds to human melanoma-associated antigen 2 (MAGE-A2). The expression of endogenous TCR was inhibited by siRNA to achieve specific recognition and cross-competitive binding of MAGE-A2, and to bind HLA class II molecules such as HLA-DP4.
It improves the broad applicability and safety of T-cell therapy, enhances its targeting ability against MAGE-A2-expressing cancer cells, and is suitable for the treatment of a variety of cancers.
Smart Images
Figure BDA0003540879570000161 
Figure BDA0003540879570000181 
Figure BDA0003540879570000271